Patents by Inventor Steven J. Henry

Steven J. Henry has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • DRY FORMULATIONS OF ANTI-SARS-COV-2 VIRUS ANTIBODIES AND COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20230270668
    Abstract: The invention generally encompasses a human-derived monoclonal antibody compositions and methods comprising a dry powder formulation for neutralizing SARS-CoV-2 and known variants thereof in a patient, comprising administering to the patient a dry powder formulation comprising the human-derived monoclonal antibody. The invention further encompasses compositions and methods comprising a dry powder formulation for treating or preventing COVID-19 and/or at least one symptom associated with COVID-19 in a patient, comprising administering to the patient a dry powder formulation comprising the human-derived monoclonal antib.
    Type: Application
    Filed: October 11, 2022
    Publication date: August 31, 2023
    Inventors: Christopher J. EMIG, Steven J. HENRY, Adela Anne VITUG, Dale J. CHRISTENSEN, Zhengrong CUI, Haiyue XU, Robert O. WILLIAMS, III
  • THERAPEUTIC COMPOUNDS
    Publication number: 20200262815
    Abstract: The present disclosure relates to a compound of formula (Ia), (Ib), (IIa), and (IIb): which are useful in the treatment of a Retroviridae viral infection including an infection caused by the HIV virus.
    Type: Application
    Filed: November 25, 2019
    Publication date: August 20, 2020
    Inventors: Michael Graupe, Steven J. Henry, John O. Link, Charles William Rowe, Roland D. Saito, Scott D. Schroeder, Dimitrios Stefanidis, Winston C. Tse, Jennifer R. Zhang
  • Therapeutic compounds
    Patent number: 10654827
    Abstract: The present disclosure relates to a compound of formula (Ia), (Ib), (IIa), and (IIb): which are useful in the treatment of a Retroviridae viral infection including an infection caused by the HIV virus.
    Type: Grant
    Filed: June 25, 2018
    Date of Patent: May 19, 2020
    Assignee: Gilead Sciences, Inc.
    Inventors: Michael Graupe, Steven J. Henry, John O. Link, Roland D. Saito, Scott D. Schroeder, Dimitrios Stefanidis, Winston C. Tse, Jennifer R. Zhang
  • DRUG DELIVERY SYSTEM FOR THE DELIVERY OF INTEGRASE INHIBITORS
    Publication number: 20190216725
    Abstract: This invention relates to novel implant drug delivery systems for long-acting delivery of integrase inhibitors. These compositions are useful for the treatment or prevention of human immunodeficiency virus (HIV) infection.
    Type: Application
    Filed: September 15, 2017
    Publication date: July 18, 2019
    Applicant: MERCK SHAPR & DOHME CORP.
    Inventors: Stephanie E. Barrett, Marian E. Gindy, Steven J. Henry, Seth P. Forster, Ryan S. Teller, Jay A. Grobler
  • THERAPEUTIC COMPOUNDS
    Publication number: 20180370950
    Abstract: The present disclosure relates to a compound of formula (Ia), (Ib), (IIa), and (IIb): which are useful in the treatment of a Retroviridae viral infection including an infection caused by the HIV virus.
    Type: Application
    Filed: June 25, 2018
    Publication date: December 27, 2018
    Inventors: Michael Graupe, Steven J. Henry, John O. Link, Charles William Rowe, Roland D. Saito, Scott D. Schroeder, Dimitrios Stefanidis, Winston C. Tse, Jennifer R. Zhang
  • Therapeutic compounds
    Patent number: 10071985
    Abstract: The present disclosure relates to a compound of formula (Ia), (Ib), (IIa), and (IIb): which are useful in the treatment of a Retroviridae viral infection including an infection caused by the HIV virus.
    Type: Grant
    Filed: August 17, 2017
    Date of Patent: September 11, 2018
    Assignee: Gilead Sciences, Inc.
    Inventors: Michael Graupe, Steven J. Henry, John O. Link, Charles William Rowe, Roland D. Saito, Scott D. Schroeder, Dimitrios Stefanidis, Winston C. Tse, Jennifer R. Zhang
  • THERAPEUTIC COMPOUNDS
    Publication number: 20180051005
    Abstract: The present disclosure relates to a compound of formula (Ia), (Ib), (IIa), and (IIb): which are useful in the treatment of a Retroviridae viral infection including an infection caused by the HIV virus.
    Type: Application
    Filed: August 17, 2017
    Publication date: February 22, 2018
    Inventors: Michael Graupe, Steven J. Henry, John O. Link, Charles William Rowe, Roland D. Saito, Scott D. Schroeder, Dimitrios Stefanidis, Winston C. Tse, Jennifer R. Zhang